MacroCure Ltd. (NASDAQ:MCUR) gapped up prior to trading on Monday . The stock had previously closed at $0.31, but opened at $1.21. MacroCure shares last traded at $2.42, with a volume of 8,783,443 shares trading hands.

Separately, Credit Suisse Group AG cut MacroCure from a “neutral” rating to an “underperform” rating and set a $1.00 target price for the company. in a research note on Monday, July 18th.

The stock has a 50-day moving average of $1.50 and a 200-day moving average of $1.20. The company’s market cap is $34.33 million.

MacroCure Ltd. is a biotechnology company. The Company is focused on developing, manufacturing and commercializing cell therapy products to address unmet needs for the treatment of chronic wounds, such as diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). Its product candidate, CureXcell, is a combination of living human white blood cells that have been activated to facilitate the healing process and stimulate wound closure.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.